What is Zenith Epigenetics?
Zenith Epigenetics is a clinical-stage biotechnology firm dedicated to pioneering novel bromodomain and extra-terminal inhibitors (BETi) for the treatment of a spectrum of cancers and other serious disorders. The company's strategic focus is on leveraging deep bromodomain biology insights to engineer targeted therapeutics, aiming to establish a leading position in oncology. By forging collaborations with premier oncology research institutions, Zenith is actively developing combination therapies designed to amplify treatment effectiveness and improve patient outcomes. Their flagship candidate, ZEN-3694, is currently undergoing clinical evaluation across various cancer indications, showing encouraging results in addressing drug resistance mechanisms.
How much funding has Zenith Epigenetics raised?
Zenith Epigenetics has raised a total of $12.3M across 2 funding rounds:
Unspecified
$8M
Private Equity
$4.3M
Unspecified (2014): $8M, investors not publicly disclosed
Private Equity (2014): $4.3M, investors not publicly disclosed
What's next for Zenith Epigenetics?
The substantial enterprise-level funding Zenith Epigenetics has attracted signals a critical growth phase, likely enabling the company to advance its lead candidate, ZEN-3694, through further clinical trials and potentially expand its pipeline. This strategic investment is expected to fuel research and development, bolster operational capacity, and support the company's mission to bring innovative BETi therapies to patients. Zenith's focus on combination strategies and addressing unmet medical needs positions it for significant impact in the competitive oncology landscape.
See full Zenith Epigenetics company page
